Classes
DEA Class; Rx
Common Brand Names; Marqibo
- Antineoplastics, Vinca Alkaloid
Description
Liposome-encapsulated formulation of vincristine sulfate, a vinca alkaloid agent
Used for the treatment of adult patients with relapsed Philadelphia chromosome-negative ALL
Neurologic toxicity (e.g., peripheral neuropathy and paralytic ileus) and myelosuppression have been reported
Indications
Contraindications
Hypersensitivity
Demyelinating conditions including Charcot-Marie-Tooth syndrome
Intrathecal administration
Adverse Effects
- Blood and lymphatic system disorders (56.6%)
- Infections (39.8%)
- General disorders and administration site condition (37.3%)
- Neuropathy (32.5%)
- Febrile neutropenia (31.3%)
- Respiratory thoracic and mediastinal disorders (20.5%)
- Investigations (24.1%)
- Gastrointestinal disorders (25.3%)
- Neutropenia (18.1%)
- Peripheral sensory and motor neuropathy (16.7%)
- Anemia (16.9%)
- Thrombocytopenia (16.9%)
- Pyrexia (14.5%)
- Fatigue (12%)
- Psychiatric disorders (10.8%)
- Cardiac disorders (10.8%)
Warnings
For IV use only; other routes may result in fatalities
Death has occurred with intrathecal administration
Do not confuse liposomal injection with vincristine injection due to different dosage recommendations; verify drug name and dose prior to administration
Pregnancy and Lactation
Based on its mechanism of action and findings from animal studies, there are insufficient data on use in pregnant women to evaluate for a drug-associated risk; drug can cause fetal harm when administered to pregnant women
If drug is used during pregnancy, or if patient becomes pregnant while taking drug, patient should be apprised of potential hazard to fetus
There are no data on presence of drug or metabolites in human milk, effects on breastfed child, or on milk production
Maximum Dosage
2.25 mg/m2 IV every 7 days.
2.25 mg/m2 IV every 7 days.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
How supplied
Vincristine sulfate liposome
intravenous injection
- 5mg/31mL (0.16mg/mL) final concentration following constitution
- Supplied as a kit that also contains sphingomyelin/cholesterol liposome injection (73.5mg/29.5mg/vial)